Shattuck Labs Inc Aktie News

AUSTIN, Texas und DURHAM, N.C., 13. Oktober 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck oder das Unternehmen) (NASDAQ: STTK), ein biopharmazeutisches Unternehmen im klinischen Stadium, das Pionierarbeit bei der Entwicklung potenzieller First-in-Class monoklonaler und bispezifischer DR3-blockierender Antikörper zur Behandlung von Patienten mit entzündlichen und immunvermittelten Erkra...

– RECEPTIVE‑HS1 Phase‑2‑Klinikstudie bei Patienten mit mäßig bis schwerer Hidradenitis suppurativa (HS) soll 2026 beginnen; Daten aus dem 16‑wöchigen Behandlungszeitraum werden im ersten Halbjahr 2028 erwartet. – HS ist die zweite Phase‑2‑Indikation für SL‑325 und erweitert die Entwicklung über IBD hinaus. – Ernennung von Shoba Ravichandran, M.D., zur Senior Vice President, Clinical Development...

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previo...

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has commenced a p...

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling...

AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced data from its Phase 1 clinical trial...

AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first q...